🔴 Outlook Therapeutics is trading 5% down today as Nasdaq and S&P 500 decline

Outlook Therapeutics is trading 5.41% down at $0.61 now amid broader market weakness on August 24, 2026.

• The Nasdaq Composite is down 0.78% and the S&P 500 is down 0.36%.
• Investors are weighing Iran sanctions, failed U.S.-Canada trade talks, tariff risks, elevated oil prices, and high Treasury yields.
• No fresh company-specific announcement was found; the latest major update was FDA approval and subsequent launch planning for LYTENAVA.